{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Pulmonary+Diseases&page=2",
    "query": {
      "condition": "Multiple Pulmonary Diseases",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Pulmonary+Diseases&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T00:58:56.968Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03038178",
      "title": "Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mycobacterium Infections, Nontuberculous",
        "Mycobacteria, Atypical"
      ],
      "interventions": [
        {
          "name": "LAI plus multi-drug regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kevin Winthrop",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2016-10",
      "completion_date": "2019-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-03-04",
      "last_synced_at": "2026-06-11T00:58:56.968Z",
      "location_count": 2,
      "location_summary": "Portland, Oregon • Tyler, Texas",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03038178"
    },
    {
      "nct_id": "NCT06218914",
      "title": "Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Colorectal Carcinoma",
        "Pancreatic Ductal Adenocarcinoma",
        "Endometrial Cancer",
        "Solid Tumor, Adult",
        "KRAS G12D"
      ],
      "interventions": [
        {
          "name": "NT-112: Autologous, engineered T Cells targeting KRAS G12D",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD0240: Autologous, engineered T Cells targeting KRAS G12D",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2024-03-22",
      "completion_date": "2043-11-18",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-06-11T00:58:56.968Z",
      "location_count": 18,
      "location_summary": "Duarte, California • Los Angeles, California • Newport Beach, California + 14 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06218914"
    },
    {
      "nct_id": "NCT06145048",
      "title": "Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer",
        "Lung Metastases"
      ],
      "interventions": [
        {
          "name": "VGT-309",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vergent Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2023-10-05",
      "completion_date": "2025-02-20",
      "has_results": true,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-06-11T00:58:56.968Z",
      "location_count": 5,
      "location_summary": "Duarte, California • Orlando, Florida • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06145048"
    },
    {
      "nct_id": "NCT03815396",
      "title": "Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alpha-1 Antitrypsin Deficiency",
        "AATD"
      ],
      "interventions": [
        {
          "name": "INBRX-101/rhAAT-Fc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inhibrx Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 31,
      "start_date": "2019-07-19",
      "completion_date": "2022-08-18",
      "has_results": false,
      "last_update_posted_date": "2022-09-13",
      "last_synced_at": "2026-06-11T00:58:56.968Z",
      "location_count": 5,
      "location_summary": "Sacramento, California • Gainesville, Florida • Miami, Florida + 2 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Hannibal",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03815396"
    },
    {
      "nct_id": "NCT06362369",
      "title": "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer",
        "Advanced Solid Tumor",
        "Melanoma",
        "Metastasis",
        "Pleural Mesothelioma",
        "Renal Cell Carcinoma",
        "MSI-High",
        "Mismatch Repair Deficiency",
        "Colorectal Cancer",
        "Hepatocellular Carcinoma",
        "Hepatocellular Cancer",
        "Renal Cell Cancer",
        "Kidney Cancer",
        "Skin Cancer",
        "Non Small Cell Lung Cancer",
        "NSCLC",
        "Anaplastic Lymphoma Kinase Genomic Tumor Aberrations",
        "ALK Genomic Tumor Aberrations"
      ],
      "interventions": [
        {
          "name": "Alintegimod",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "7 Hills Pharma, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 126,
      "start_date": "2024-08-23",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-06-11T00:58:56.968Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Lake Mary, Florida • Lebanon, New Hampshire + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06362369"
    },
    {
      "nct_id": "NCT07610395",
      "title": "Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rhinovirus Infection"
      ],
      "interventions": [
        {
          "name": "VPV 1000 mg",
          "type": "DRUG"
        },
        {
          "name": "VPV 500 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Altesa Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 180,
      "start_date": "2026-05-01",
      "completion_date": "2027-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-06-11T00:58:56.968Z",
      "location_count": 14,
      "location_summary": "Tempe, Arizona • Newport Beach, California • San Diego, California + 11 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Snellville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07610395"
    },
    {
      "nct_id": "NCT04766931",
      "title": "The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "FB2001",
          "type": "DRUG"
        },
        {
          "name": "FB2001 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Frontier Biotechnologies Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 88,
      "start_date": "2021-03-17",
      "completion_date": "2022-08-12",
      "has_results": false,
      "last_update_posted_date": "2022-11-28",
      "last_synced_at": "2026-06-11T00:58:56.968Z",
      "location_count": 1,
      "location_summary": "Secaucus, New Jersey",
      "locations": [
        {
          "city": "Secaucus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04766931"
    },
    {
      "nct_id": "NCT02097641",
      "title": "Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Distress Syndrome, Adult"
      ],
      "interventions": [
        {
          "name": "Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Plasma-Lyte A",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Michael A. Matthay",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2014-03-15",
      "completion_date": "2018-02-09",
      "has_results": true,
      "last_update_posted_date": "2019-04-10",
      "last_synced_at": "2026-06-11T00:58:56.968Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Stanford, California • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02097641"
    },
    {
      "nct_id": "NCT04806620",
      "title": "Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Post-Acute COVID-19 Syndrome",
        "ME/CFS",
        "Rheumatic Arthritis",
        "Juvenile Rheumatoid Arthritis (JRA)",
        "Psoriatic Arthritis (PsA)",
        "Ankylosing Spondylitis (AS)",
        "Autoimmune Encephalitis",
        "Celiac Disease",
        "Celiac Disease in Children",
        "Chronic Lyme Disease",
        "Post-treatment Lyme Disease Syndrome",
        "Crohn's Disease",
        "Dysautonomia",
        "Anorexia Nervosa",
        "Bulimia Nervosa",
        "ARFID",
        "Avoidant / Restrictive Food Intake Disorder",
        "Ehlers Danlos Syndrome",
        "Endometriosis",
        "Fibromyalgia (FM)",
        "Long COVID",
        "Lupus",
        "Migraines",
        "Mast Cell Activation Syndrome",
        "Multiple Sclerosis",
        "Myalgic Encephalomyelitis (ME)",
        "Myasthenia Gravis, Generalized",
        "Myasthenia Gravis in Children",
        "Narcolepsy",
        "Obsessive Compulsive Disorder (OCD)",
        "PANDAS",
        "Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)",
        "POTS - Postural Orthostatic Tachycardia Syndrome",
        "General Anxiety Disorder, Social Anxiety Disorder",
        "PTSD - Post Traumatic Stress Disorder",
        "Psoriasis",
        "Traumatic Brain Injury",
        "Tourette's Syndrome",
        "Inflammatory Bowel Disease (IBD)",
        "Autoimmune Diseases",
        "Neurological Diseases or Conditions",
        "Psychiatric Disorder",
        "Sjogren's Syndrome",
        "Ulcerative Colitis and Crohn's Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Brain Inflammation Collaborative",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 10000,
      "start_date": "2023-07-05",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-06-11T00:58:56.968Z",
      "location_count": 1,
      "location_summary": "Delafield, Wisconsin",
      "locations": [
        {
          "city": "Delafield",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04806620"
    },
    {
      "nct_id": "NCT06701682",
      "title": "JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Respiratory Distress Syndrome (ARDS)",
        "ARDS",
        "ARDS (Acute Respiratory Distress Syndrome)",
        "Acute Respiratory Distress Syndrome"
      ],
      "interventions": [
        {
          "name": "Cohort A: vilobelimab",
          "type": "DRUG"
        },
        {
          "name": "Cohort A: placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PPD Development, LP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2025-06-21",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-06-11T00:58:56.968Z",
      "location_count": 40,
      "location_summary": "Birmingham, Alabama • Fresno, California • Long Beach, California + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06701682"
    }
  ]
}